[HTML][HTML] Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review
Background Chemotherapy in the multimodality treatment of osteosarcoma has improved
survival. Reported outcomes on adult patients are limited. Poor necrosis rates post …
survival. Reported outcomes on adult patients are limited. Poor necrosis rates post …
[PDF][PDF] Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review
GM O'Kane, KA Cadoo, EM Walsh, R Emerson… - 2015 - researchgate.net
Background: Chemotherapy in the multimodality treatment of osteosarcoma has improved
survival. Reported outcomes on adult patients are limited. Poor necrosis rates post …
survival. Reported outcomes on adult patients are limited. Poor necrosis rates post …
Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review
GM O'Kane, KA Cadoo, EM Walsh… - Clinical Sarcoma …, 2015 - go.gale.com
Background Chemotherapy in the multimodality treatment of osteosarcoma has improved
survival. Reported outcomes on adult patients are limited. Poor necrosis rates post …
survival. Reported outcomes on adult patients are limited. Poor necrosis rates post …
Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review.
GM O'Kane, KA Cadoo, EM Walsh… - Clinical Sarcoma …, 2015 - europepmc.org
Background Chemotherapy in the multimodality treatment of osteosarcoma has improved
survival. Reported outcomes on adult patients are limited. Poor necrosis rates post …
survival. Reported outcomes on adult patients are limited. Poor necrosis rates post …
[PDF][PDF] Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review
GM O'Kane, KA Cadoo, EM Walsh, R Emerson… - 2015 - scienceopen.com
Background: Chemotherapy in the multimodality treatment of osteosarcoma has improved
survival. Reported outcomes on adult patients are limited. Poor necrosis rates post …
survival. Reported outcomes on adult patients are limited. Poor necrosis rates post …
[HTML][HTML] Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review
GM O'Kane, KA Cadoo… - Clinical …, 2015 - clinicalsarcomaresearch …
Chemotherapy in the multimodality treatment of osteosarcoma has improved survival.
Reported outcomes on adult patients are limited. Poor necrosis rates post neoadjuvant …
Reported outcomes on adult patients are limited. Poor necrosis rates post neoadjuvant …
Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review
GM O'Kane, KA Cadoo, EM Walsh, R Emerson… - Clinical Sarcoma …, 2015 - infona.pl
Background Chemotherapy in the multimodality treatment of osteosarcoma has improved
survival. Reported outcomes on adult patients are limited. Poor necrosis rates post …
survival. Reported outcomes on adult patients are limited. Poor necrosis rates post …
[HTML][HTML] Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review
GM O'Kane, KA Cadoo, EM Walsh… - Clinical Sarcoma …, 2015 - ncbi.nlm.nih.gov
Background Chemotherapy in the multimodality treatment of osteosarcoma has improved
survival. Reported outcomes on adult patients are limited. Poor necrosis rates post …
survival. Reported outcomes on adult patients are limited. Poor necrosis rates post …
Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review
GM O'Kane, KA Cadoo, EM Walsh… - Clinical sarcoma …, 2015 - pubmed.ncbi.nlm.nih.gov
Background Chemotherapy in the multimodality treatment of osteosarcoma has improved
survival. Reported outcomes on adult patients are limited. Poor necrosis rates post …
survival. Reported outcomes on adult patients are limited. Poor necrosis rates post …
Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review
GM OKane, KA Cadoo, EM Walsh… - Clinical Sarcoma …, 2015 - search.proquest.com
Background Osteosarcoma is a rare tumour type occurring with an incidence of 0.2-3/1,
00,000 per year in Europe [1]. Despite this, it is the most common primary tumour of bone …
00,000 per year in Europe [1]. Despite this, it is the most common primary tumour of bone …